周剂量多西他赛联合卡培他滨治疗晚期胃癌的疗效观察

目的观察周剂量多西他赛联合卡培他滨治疗晚期胃癌的疗效及不良反应。方法多西他赛每次剂量25mg·m-2,d1、d8、d15,卡培他滨每日2000mg·m-2,分2次口服,d1～d14,28天为1周期,连用2周期以后评价疗效。结果 40例晚期胃癌患者均可评价疗效,其中完全缓解0例(0%),部分缓解18例(45.0%),病情稳定16例(40.0%),病情进展6例(15.0%),总有效率为45.0%,中位疾病无进展时间(TTP)为6.35月。不良反应多为骨髓抑制、胃肠道反应、手足综合征,严重不良反应主要为白细胞下降(35%)。结论周剂量多西他赛联合卡培他滨治疗晚期胃癌近期疗效好,严重不良反应少,患者耐受性高,可改善患者的生存质量。

------------------

Objective To observe the therapeutic effects and adverse reaction of weekly Docetaxol plus Capecitabine on advanced gastric cancer. Methods 40 patients with advanced gastric cancer were given Docetaxol at dose of 25 mg·m-2 at d1, d8, d15, and Capecitabine of 2?000 mg·m-2 per day (bid) on d1 to d14, and this regimen constitutes one 28-day treatment cycle. The therapeutic effects were evaluated after 2 treatment cycles. Results The therapeutic effects were evaluated in all 40 cases. Among the 40 patients, nobody had complete response (0%), partial response was achieved in 18 (45.0%), stable disease in 16 (40.0%) and progressive disease in 6 (15.0%). The total effective rate was 45.0%, and the median TTP was 6.35 months. Adverse effects such as myelosuppression, gastrointestinal reaction and hand-foot syndrome were observed, but serious adverse effect mainly was leucopenia (35%). Conclusion Weekly Docetaxol plus Capecitabine had good short-term effects, low incidence of serious adverse effects and good tolerance on patients with advanced gastric carcinoma; meanwhile, it could improve life quality of these patients.